Myovant Sciences Ltd (NASDAQ:MYOV)‘s stock had its “buy” rating reissued by research analysts at Cowen and Company in a note issued to investors on Tuesday.

Other analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 31st. Evercore ISI began coverage on shares of Myovant Sciences in a research note on Wednesday, August 16th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $18.20.

Myovant Sciences (MYOV) traded up 1.36% on Tuesday, hitting $14.88. The stock had a trading volume of 150,312 shares. Myovant Sciences has a one year low of $10.25 and a one year high of $18.85. The stock’s 50 day moving average is $13.46 and its 200 day moving average is $13.46. The stock’s market cap is $905.36 million.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Deerfield Management Co. acquired a new position in Myovant Sciences in the 4th quarter valued at about $18,619,000. RA Capital Management LLC boosted its position in Myovant Sciences by 56.6% during the first quarter. RA Capital Management LLC now owns 2,348,422 shares of the company’s stock worth $27,570,000 after acquiring an additional 848,422 shares during the last quarter. Norges Bank acquired a new stake in Myovant Sciences during the fourth quarter worth approximately $9,763,000. Eventide Asset Management LLC acquired a new stake in Myovant Sciences during the first quarter worth approximately $3,463,000. Finally, Perceptive Advisors LLC acquired a new stake in Myovant Sciences during the fourth quarter worth approximately $2,815,000.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with's FREE daily email newsletter.